Latest On BioPharmX Corporation (BPMX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-01-02 15:17 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-12-13 03:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-15 11:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 11:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 17:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 00:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 12:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-10 08:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-31 16:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-19 08:16 EST | Stock Split | A stock split has occured on May 19, 2020 with a split factor of 1:12. | Neutral | |
| 2020-05-14 02:00 EST | News | BioPharmX shareholders back tie-up with Timber Pharmaceuticals | N/A | |
| 2020-05-03 08:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 00:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-31 00:16 EST | Earnings Estimate | An EPS average of -$0.06 is estimated for the quarter ending on July 31, 2020. | Buy | |
| 2020-03-28 00:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 23:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-07 23:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-06 23:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-31 03:13 EST | Analyst Rating | The Analyst Target Price has increased from $1.63 to $2.25. | Buy | |
| 2020-01-29 23:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on June 13, 2017, with -$0.08 earnings per share. | Sell | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on April 30, 2019, with -$0.38 earnings per share. | Sell | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on June 11, 2019, with -$0.38 earnings per share. | Sell | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on June 14, 2018, with -$0.03 earnings per share. | Buy | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on October 31, 2019, with -$0.14 earnings per share. | Buy | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on September 30, 2019, with -$0.14 earnings per share. | Buy | |
| 2020-01-28 03:19 EST | Earnings | Earnings have been released on June 30, 2019, with -$0.22 earnings per share. | Buy | |
| 2020-01-16 23:18 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-16 23:15 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-16 23:15 EST | Earnings Estimate | An EPS average of -$0.07 is estimated for the quarter ending on April 30, 2020. | Buy | |
| 2019-12-10 18:16 EST | News | BioPharmX EPS beats by $0.08 | N/A | |
| 2019-11-27 23:14 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-26 23:15 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-22 23:12 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-15 23:13 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-06 23:14 EST | Financials | Company financials have been released. | Neutral | |
| 2019-09-09 08:19 EST | News | BioPharmX EPS beats by $0.12 | N/A | |
| 2019-09-09 01:05 EST | Earnings | Earnings have been released on September 9, 2019, with -$0.22 earnings per share. | Buy | |
| 2019-07-31 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2019-04-30 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2019-03-14 01:05 EST | Earnings | Earnings have been released on March 14, 2019, with -$0.25 earnings per share. | Buy | |
| 2019-01-31 00:05 EST | Financials | Company financials have been released. | Neutral | |
| 2018-12-06 00:05 EST | Earnings | Earnings have been released on December 6, 2018, with -$0.50 earnings per share. | Neutral | |
| 2018-10-31 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2018-08-30 01:05 EST | Earnings | Earnings have been released on August 30, 2018, with -$0.02 earnings per share. | Neutral | |
| 2018-07-31 01:05 EST | Financials | Company financials have been released. | Neutral | |
About BioPharmX Corporation (BPMX):
BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trials for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of papulopustular rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in Campbell, California.
General
- Name BioPharmX Corporation
- Symbol BPMX
- Type Common Stock
- Exchange NYSE
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 3
- Last Split Factor1:12
- Last Split Date2020-05-19
- Fiscal Year EndJanuary
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.biopharmx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 695.03
- Price/Book (Most Recent Quarter) 7.9
View More
Financials
- Most Recent Quarter 2020-01-31
- Return on Assets -209%
- Return on Equity -2020%
- Earnings Per Share -$1.56
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 776821
- EBITDA -13684500
- Analyst Target Price $2.25
- Book Value Per Share $0.05
View More
Share Statistics
- Shares Outstanding 1.52 million
- Shares Float 16.07 million
- % Held by Insiders 1274%
- % Held by Institutions 1.93%
- Shares Short 91024
- Shares Short Prior Month 86618
- Short Ratio 1.33
- Short % of Float 7%
- Short % of Shares Outstanding 6%
View More
Technicals
- Beta 0.63
- 52 Week High $7.79
- 52 Week Low $0.26
- 50 Day Moving Average 3.64
- 200 Day Moving Average 0.77
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
View More
BioPharmX Corporation (BPMX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
BioPharmX Corporation (BPMX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-04-30 | 2020-06-12 | -$1.34 | -$0.84 | -59.52% | |
| 2020-01-31 | 2020-01-31 | $N/A | -$0.09 | -$0.08 | -12.5% |
| 2019-10-31 | 2019-10-31 | $N/A | -$0.14 | -$0.22 | 36.36% |
| 2019-07-31 | 2019-07-31 | $N/A | -$0.22 | -$0.33 | 33.33% |
| 2019-04-30 | 2019-04-30 | $N/A | -$0.38 | -$0.26 | -46.15% |
| 2019-01-31 | 2019-03-14 | $5000 | -$0.25 | -$0.50 | 50% |
| 2018-10-31 | 2018-12-06 | $10000 | -$0.50 | -$0.50 | 0% |
| 2018-07-31 | 2018-08-30 | $24000 | -$0.50 | -$0.50 | 0% |
| 2018-04-30 | 2018-06-14 | $18000 | -$0.03 | -$0.04 | 25% |
| 2017-10-31 | 2017-12-07 | $18000 | -$0.05 | -$0.05 | 0% |
| 2017-07-31 | 2017-09-13 | $17000 | -$0.05 | -$0.06 | 16.67% |
| 2017-04-30 | 2017-06-13 | $19000 | -$0.08 | -$0.07 | -14.29% |
| 2017-01-31 | 2017-03-23 | $15000 | -$0.09 | -$0.10 | 10% |
BioPharmX Corporation (BPMX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jan 31 2020 | Oct 31 2019 | Jul 31 2019 | Apr 30 2019 | Jan 31 2019 |
|---|---|---|---|---|---|
| Research Development | 6000 | 740000 | 1.38 million | 2.2 million | 1.21 million |
| Income Before Tax | -1.31 million | -2.11 million | -2.65 million | -3.62 million | -4.06 million |
| Selling General Administrative | 1.26 million | 1.38 million | 1.29 million | 1.44 million | 2.19 million |
| Gross Profit | N/A | N/A | N/A | N/A | 2000 |
| Ebit | -1.27 million | -2.12 million | -2.66 million | -3.64 million | -3.39 million |
| Operating Income | -1.27 million | -2.12 million | -2.66 million | -3.64 million | -3.39 million |
| Income Tax Expense | N/A | N/A | N/A | 2000 | 2000 |
| Total Revenue | N/A | N/A | N/A | N/A | 5000 |
| Cost of Revenue | N/A | N/A | N/A | N/A | 3000 |
| Total Other Income Expense Net | -39000 | 7000 | 14000 | 19000 | -664500 |
| Net Income From Continuing Operations | -1.31 million | -2.11 million | -2.65 million | -3.62 million | -4.06 million |
| Net Income Applicable to Common Shares | -1.31 million | -2.11 million | -2.65 million | -3.62 million | -4.06 million |
Cash Flow:
| Date | Jan 31 2020 | Oct 31 2019 | Jul 31 2019 | Apr 30 2019 | Jan 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -123000 | -250000 | -248000 | -178000 | -24000 |
| Total Cash Flow from Investing Activities | N/A | N/A | -24000 | -6000 | -30000 |
| Net Borrowings | 616000 | -11000 | -9000 | -5000 | -5000 |
| Total Cash Flow from Financial Activities | 616000 | 378000 | 3.25 million | 3.55 million | 3.58 million |
| Change to Operating Activities | -166000 | -123000 | -514000 | 272000 | -582000 |
| Change in Cash | -700000 | -1.86 million | 7000 | 214000 | 51000 |
| Total Cash from Operating Activities | -1.32 million | -2.24 million | -3.22 million | -3.33 million | -3.5 million |
| Depreciation | 15000 | 16000 | 16000 | 14000 | 14000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | -3000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 250000 | 229000 | 175000 | 182000 | 1.15 million |
| Capital Expenditures | N/A | N/A | 24000 | 6000 | 30000 |
Balance Sheet:
| Date | Jan 31 2020 | Oct 31 2019 | Jul 31 2019 | Apr 30 2019 | Jan 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 2.47 million | 2.41 million | 2.95 million | 3.51 million | 2.36 million |
| Total Stockholder Equity | -339000 | 717000 | 2.21 million | 1.42 million | 1.3 million |
| Other Current Liabilities | 398000 | 20000 | 99000 | N/A | N/A |
| Total Assets | 2.13 million | 3.13 million | 5.17 million | 4.93 million | 3.65 million |
| Common Stock | 15000 | 15000 | 14000 | 10000 | 218000 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -88.22 million | -86.92 million | -84.8 million | -82.16 million | -78.53 million |
| Other Liabilities | N/A | N/A | 44000 | 19000 | 34000 |
| Other Assets | 115000 | 121000 | 121000 | 121000 | 121000 |
| Cash | 727000 | 1.43 million | 3.29 million | 3.28 million | 3.07 million |
| Total Current Liabilities | 1.68 million | 1.55 million | 2.02 million | 2.53 million | 2.3 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 1.03 million | 1.19 million | 1.27 million | 1.28 million | 148000 |
| Total Current Assets | 986000 | 1.82 million | 3.77 million | 3.53 million | 3.39 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -339000 | 717000 | 2.21 million | 1.42 million | 1.3 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | 956000 | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 564000 | 687000 | 937000 | 1.19 million | 1.36 million |
BioPharmX Corporation (BPMX) Chart:
BioPharmX Corporation (BPMX) News:
Below you will find a list of latest news for BioPharmX Corporation (BPMX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
BioPharmX Corporation (BPMX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
BioPharmX Corporation (BPMX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920080671/0001104659-20-080671-index.htm |
| 2020-02-25 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1504167/000000000020001676/0000000000-20-001676-index.htm |
| 2020-05-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1504167/000090266420002221/0000902664-20-002221-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000478/0000905718-20-000478-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000480/0000905718-20-000480-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000482/0000905718-20-000482-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000484/0000905718-20-000484-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000488/0000905718-20-000488-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000490/0000905718-20-000490-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000492/0000905718-20-000492-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000494/0000905718-20-000494-index.htm |
| 2020-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000496/0000905718-20-000496-index.htm |
| 2020-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000498/0000905718-20-000498-index.htm |
| 2020-05-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000502/0000905718-20-000502-index.htm |
| 2020-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000504/0000905718-20-000504-index.htm |
| 2020-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000506/0000905718-20-000506-index.htm |
| 2020-05-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000508/0000905718-20-000508-index.htm |
| 2020-05-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000516/0000905718-20-000516-index.htm |
| 2020-06-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000550/0000905718-20-000550-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000552/0000905718-20-000552-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000554/0000905718-20-000554-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000556/0000905718-20-000556-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000558/0000905718-20-000558-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000560/0000905718-20-000560-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1504167/000090571820000562/0000905718-20-000562-index.htm |
| 2020-02-20 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000104746920000945/0001047469-20-000945-index.htm |
| 2020-03-30 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000104746920001894/0001047469-20-001894-index.htm |
| 2020-04-01 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1504167/000104746920001984/0001047469-20-001984-index.htm |
| 2020-04-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1504167/000104746920002604/0001047469-20-002604-index.htm |
| 2020-03-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1504167/000110465920040019/0001104659-20-040019-index.htm |
| 2020-04-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920051596/0001104659-20-051596-index.htm |
| 2020-04-27 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000110465920051598/0001104659-20-051598-index.htm |
| 2020-05-07 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000110465920057625/0001104659-20-057625-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920059526/0001104659-20-059526-index.htm |
| 2020-05-11 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000110465920059528/0001104659-20-059528-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920060888/0001104659-20-060888-index.htm |
| 2020-05-13 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000110465920060889/0001104659-20-060889-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920062661/0001104659-20-062661-index.htm |
| 2020-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920065467/0001104659-20-065467-index.htm |
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920069424/0001104659-20-069424-index.htm |
| 2020-06-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1504167/000110465920072899/0001104659-20-072899-index.htm |
| 2020-06-16 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1504167/000110465920073826/0001104659-20-073826-index.htm |
| 2020-07-02 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000110465920080671/0001104659-20-080671-index.htm |
| 2020-05-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1504167/000138713120005292/0001387131-20-005292-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000150416720000004/0001504167-20-000004-index.htm |
| 2020-03-23 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1504167/000155837020003019/0001558370-20-003019-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000155837020003354/0001558370-20-003354-index.htm |
| 2020-03-30 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000155837020003355/0001558370-20-003355-index.htm |
| 2020-04-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1504167/000155837020003636/0001558370-20-003636-index.htm |
| 2020-04-06 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1504167/000155837020003637/0001558370-20-003637-index.htm |
| 2020-03-31 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1504167/999999999520000649/9999999995-20-000649-index.htm |